Details of the Drug

General Information of Drug (ID: DMRQD04)

Drug Name
Tramadol
Synonyms Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 263.37
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 300 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.6-1.9 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 75% [3]
Clearance
The clearance of drug is 3.73 mL/min/kg in renal impairment patients [5]
Elimination
Tramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys, accounting for 90% of the excretion while the remaining 10% is excreted through feces [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 6 hours [7]
Metabolism
The drug is metabolized via the liver [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.271 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.8% [10]
Vd
The volume of distribution (Vd) of drug is 2.6-2.9 L/kg [11]
Chemical Identifiers
Formula
C16H25NO2
IUPAC Name
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
Canonical SMILES
CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
InChI
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
InChIKey
TVYLLZQTGLZFBW-ZBFHGGJFSA-N
Cross-matching ID
PubChem CID
33741
ChEBI ID
CHEBI:75725
CAS Number
123154-38-1
DrugBank ID
DB00193
TTD ID
D05GKD
VARIDT ID
DR00088
INTEDE ID
DR1627
ACDINA ID
D00693

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Modulator [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [15]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2C receptor (HTR2C) DTT HTR2C 1.02E-02 -0.45 -0.37
5-HT 2C receptor (HTR2C) DTT HTR2C 2.27E-01 0.27 0.6
P-glycoprotein 1 (ABCB1) DTP P-GP 1.19E-01 -1.32E-01 -2.77E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 1.65E-01 -1.47E-01 -4.48E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 8.03E-01 9.92E-03 4.89E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.42E-01 -4.97E-02 -3.73E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 9.90E-01 3.10E-03 1.75E-02
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 5.35E-01 1.10E-02 1.19E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.59E-01 6.29E-02 3.14E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 4.84E-01 -8.38E-02 -8.46E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.66E-01 4.25E-02 1.20E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.75E-01 5.15E-02 3.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tramadol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Tramadol and Dextropropoxyphene. Pain [MG30-MG3Z] [69]
Oxymorphone DM65AGJ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Oxymorphone. Pain [MG30-MG3Z] [70]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Tramadol and Levorphanol. Pain [MG30-MG3Z] [70]
Hydromorphone DMHP21E Major Increased risk of lowers seizure threshold by the combination of Tramadol and Hydromorphone. Pain [MG30-MG3Z] [70]
Codeine DMJX6ZG Major Increased risk of lowers seizure threshold by the combination of Tramadol and Codeine. Pain [MG30-MG3Z] [70]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Tramadol and Flavoxate. Pain [MG30-MG3Z] [71]
Methamphetamine DMPM4SK Major Increased risk of lowers seizure threshold by the combination of Tramadol and Methamphetamine. Pain [MG30-MG3Z] [70]
Hydrocodone DMQ2JO5 Major Additive hypotensive effects by the combination of Tramadol and Hydrocodone. Pain [MG30-MG3Z] [70]
Meperidine DMX4GND Major Additive hypotensive effects by the combination of Tramadol and Meperidine. Pain [MG30-MG3Z] [70]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Tramadol and Oxycodone. Pain [MG30-MG3Z] [70]
⏷ Show the Full List of 10 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Tramadol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Bethanechol. Abnormal micturition [MF50] [70]
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Tramadol and Methylene blue. Acquired methaemoglobinaemia [3A93] [72]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Tramadol and Ivosidenib. Acute myeloid leukaemia [2A60] [73]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Tramadol and Midostaurin. Acute myeloid leukaemia [2A60] [74]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Tramadol and Idarubicin. Acute myeloid leukaemia [2A60] [74]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Tramadol and Daunorubicin. Acute myeloid leukaemia [2A60] [74]
Arn-509 DMT81LZ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Arn-509. Acute myeloid leukaemia [2A60] [70]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Tramadol and Gilteritinib. Acute myeloid leukaemia [2A60] [75]
Oliceridine DM6MDCF Major Additive hypotensive effects by the combination of Tramadol and Oliceridine. Acute pain [MG31] [70]
Chlorzoxazone DMCYVDT Major Additive CNS depression effects by the combination of Tramadol and Chlorzoxazone. Acute pain [MG31] [76]
Scopolamine DMOM8AL Moderate Additive antimotility effects by the combination of Tramadol and Scopolamine. Addictive disorder [6C50-6C5Z] [71]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Tramadol and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [74]
Tacrine DM51FY6 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Tacrine. Alzheimer disease [8A20] [70]
Galantamine DMEO794 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Galantamine. Alzheimer disease [8A20] [70]
Rivastigmine DMG629M Major Increased risk of lowers seizure threshold by the combination of Tramadol and Rivastigmine. Alzheimer disease [8A20] [70]
Donepezil DMIYG7Z Major Increased risk of lowers seizure threshold by the combination of Tramadol and Donepezil. Alzheimer disease [8A20] [70]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Tramadol and Metronidazole. Amoebiasis [1A36] [77]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Tramadol and Ivabradine. Angina pectoris [BA40] [78]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Tramadol and Bepridil. Angina pectoris [BA40] [74]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Tramadol and Dronedarone. Angina pectoris [BA40] [74]
Marinol DM70IK5 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Marinol. Anorexia nervosa [6B80] [70]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Tramadol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [79]
Butalbital DM9J04X Major Additive CNS depression effects by the combination of Tramadol and Butalbital. Anxiety disorder [6B00-6B0Z] [76]
Buspirone DMBS632 Major Additive CNS depression effects by the combination of Tramadol and Buspirone. Anxiety disorder [6B00-6B0Z] [80]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Tramadol and Clorazepate. Anxiety disorder [6B00-6B0Z] [81]
Alprazolam DMC7XDN Major Additive CNS depression effects by the combination of Tramadol and Alprazolam. Anxiety disorder [6B00-6B0Z] [76]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Tramadol and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [81]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Tramadol and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [76]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Tramadol and Halazepam. Anxiety disorder [6B00-6B0Z] [76]
Chlordiazepoxide DMTN5XI Major Additive CNS depression effects by the combination of Tramadol and Chlordiazepoxide. Anxiety disorder [6B00-6B0Z] [76]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Tramadol and Chlormezanone. Anxiety disorder [6B00-6B0Z] [76]
Clobazam - Lundbeck DMW1OQ0 Major Additive CNS depression effects by the combination of Tramadol and Clobazam - Lundbeck. Anxiety disorder [6B00-6B0Z] [76]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Tramadol and Oxazepam. Anxiety disorder [6B00-6B0Z] [76]
Promazine DMZAL7W Major Additive CNS depression effects by the combination of Tramadol and Promazine. Appearance/behaviour symptom [MB23] [76]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Tramadol and Cilostazol. Arterial occlusive disease [BD40] [74]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Tramadol and Posaconazole. Aspergillosis [1F20] [74]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Levalbuterol. Asthma [CA23] [82]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Terbutaline. Asthma [CA23] [83]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Pirbuterol. Asthma [CA23] [83]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Isoetharine. Asthma [CA23] [83]
Aminophylline DML2NIB Major Increased risk of lowers seizure threshold by the combination of Tramadol and Aminophylline. Asthma [CA23] [70]
Ephedrine DMMV0KW Major Increased risk of lowers seizure threshold by the combination of Tramadol and Ephedrine. Asthma [CA23] [70]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Salbutamol. Asthma [CA23] [82]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Formoterol. Asthma [CA23] [83]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Tramadol and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [74]
Lisdexamfetamine DM6W8V5 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [70]
Methylphenidate DM7SJD6 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Methylphenidate. Attention deficit hyperactivity disorder [6A05] [70]
Desipramine DMT2FDC Major Increased risk of lowers seizure threshold by the combination of Tramadol and Desipramine. Attention deficit hyperactivity disorder [6A05] [70]
Ofloxacin DM0VQN3 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Ofloxacin. Bacterial infection [1A00-1C4Z] [70]
Ciprofloxacin XR DM2NLS9 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [70]
Erythromycin DM4K7GQ Moderate Decreased metabolism of Tramadol caused by Erythromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [74]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Tramadol and Clarithromycin. Bacterial infection [1A00-1C4Z] [74]
Ertapenem DM4S3O8 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Ertapenem. Bacterial infection [1A00-1C4Z] [70]
Meropenem DM62UHC Major Increased risk of lowers seizure threshold by the combination of Tramadol and Meropenem. Bacterial infection [1A00-1C4Z] [70]
Trovafloxacin DM6AN32 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Trovafloxacin. Bacterial infection [1A00-1C4Z] [70]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Tramadol and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [74]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Tramadol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [84]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Tramadol and Linezolid. Bacterial infection [1A00-1C4Z] [85]
Gemifloxacin DMHT34O Major Increased risk of lowers seizure threshold by the combination of Tramadol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [70]
Imipenem DMI9FBP Major Increased risk of lowers seizure threshold by the combination of Tramadol and Imipenem. Bacterial infection [1A00-1C4Z] [70]
Norfloxacin DMIZ6W2 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Norfloxacin. Bacterial infection [1A00-1C4Z] [70]
ABT-492 DMJFD2I Major Increased risk of lowers seizure threshold by the combination of Tramadol and ABT-492. Bacterial infection [1A00-1C4Z] [70]
Levofloxacin DMS60RB Major Increased risk of lowers seizure threshold by the combination of Tramadol and Levofloxacin. Bacterial infection [1A00-1C4Z] [70]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Tramadol and Moxifloxacin. Bacterial infection [1A00-1C4Z] [86]
Lomefloxacin DMVRH9C Major Increased risk of lowers seizure threshold by the combination of Tramadol and Lomefloxacin. Bacterial infection [1A00-1C4Z] [70]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Tramadol and Telithromycin. Bacterial infection [1A00-1C4Z] [74]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Tramadol and Retigabine. Behcet disease [4A62] [74]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Tramadol and Cariprazine. Bipolar disorder [6A60] [76]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Loperamide. Bowel habit change [ME05] [87]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Tramadol and Eribulin. Breast cancer [2C60-2C6Y] [74]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Tramadol and Lapatinib. Breast cancer [2C60-2C6Y] [74]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Tramadol and Tamoxifen. Breast cancer [2C60-2C6Y] [74]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Tramadol and Toremifene. Breast cancer [2C60-2C6Y] [74]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Tramadol and Bosutinib. Breast cancer [2C60-2C6Y] [78]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Tramadol and Grepafloxacin. Bronchitis [CA20] [84]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Tramadol and Sotalol. Cardiac arrhythmia [BC9Z] [74]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Tramadol and Dofetilide. Cardiac arrhythmia [BC9Z] [74]
Secobarbital DM14RF5 Major Additive CNS depression effects by the combination of Tramadol and Secobarbital. Chronic insomnia [7A00] [76]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Tramadol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [88]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Olodaterol. Chronic obstructive pulmonary disease [CA22] [83]
Pregabalin DMDVP3B Major Additive CNS depression effects by the combination of Tramadol and Pregabalin. Chronic obstructive pulmonary disease [CA22] [89]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Vilanterol. Chronic obstructive pulmonary disease [CA22] [82]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Salmeterol. Chronic obstructive pulmonary disease [CA22] [83]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Indacaterol. Chronic obstructive pulmonary disease [CA22] [83]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Arformoterol. Chronic obstructive pulmonary disease [CA22] [83]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Tramadol and Dihydrocodeine. Chronic pain [MG30] [69]
Morphine DMRMS0L Major Increased risk of lowers seizure threshold by the combination of Tramadol and Morphine. Chronic pain [MG30] [70]
Levomilnacipran DMV26S8 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Levomilnacipran. Chronic pain [MG30] [85]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Tramadol and Oxaliplatin. Colorectal cancer [2B91] [74]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Isoproterenol. Conduction disorder [BC63] [82]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Tramadol and Olopatadine. Conjunctiva disorder [9A60] [90]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Halothane. Corneal disease [9A76-9A78] [74]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Tramadol and Propofol. Corneal disease [9A76-9A78] [91]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Sevoflurane. Corneal disease [9A76-9A78] [74]
Lidocaine DML4ZOT Major Increased risk of lowers seizure threshold by the combination of Tramadol and Lidocaine. Corneal disease [9A76-9A78] [70]
Cocaine DMSOX7I Major Increased risk of lowers seizure threshold by the combination of Tramadol and Cocaine. Corneal disease [9A76-9A78] [92]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Tramadol and Alfentanil. Corneal disease [9A76-9A78] [70]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Tramadol and Remifentanil. Corneal disease [9A76-9A78] [70]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Tramadol and Probucol. Coronary atherosclerosis [BA80] [74]
Oxtriphylline DMLHSE3 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Oxtriphylline. Cough [MD12] [70]
Methadone DMTW6IU Major Increased risk of lowers seizure threshold by the combination of Tramadol and Methadone. Cough [MD12] [74]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Tramadol and Clofazimine. Crohn disease [DD70] [93]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Tramadol and Mifepristone. Cushing syndrome [5A70] [74]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Tramadol and Pasireotide. Cushing syndrome [5A70] [74]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Tramadol and Osilodrostat. Cushing syndrome [5A70] [78]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Tramadol and Ethanol. Cystitis [GC00] [90]
Sertraline DM0FB1J Major Decreased metabolism of Tramadol caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [94]
Trimipramine DM1SC8M Major Increased risk of lowers seizure threshold by the combination of Tramadol and Trimipramine. Depression [6A70-6A7Z] [70]
Imipramine DM2NUH3 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Imipramine. Depression [6A70-6A7Z] [70]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Tramadol and Fluoxetine. Depression [6A70-6A7Z] [94]
Nortriptyline DM4KDYJ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Nortriptyline. Depression [6A70-6A7Z] [70]
Vilazodone DM4LECQ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Vilazodone. Depression [6A70-6A7Z] [85]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Tramadol and Nefazodone. Depression [6A70-6A7Z] [85]
Paroxetine DM5PVQE Major Increased risk of lowers seizure threshold by the combination of Tramadol and Paroxetine. Depression [6A70-6A7Z] [94]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Tramadol and Selegiline. Depression [6A70-6A7Z] [85]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Tramadol and Vortioxetine. Depression [6A70-6A7Z] [94]
Duloxetine DM9BI7M Major Increased risk of lowers seizure threshold by the combination of Tramadol and Duloxetine. Depression [6A70-6A7Z] [85]
Isocarboxazid DMAF1NB Major Increased risk of lowers seizure threshold by the combination of Tramadol and Isocarboxazid. Depression [6A70-6A7Z] [85]
Milnacipran DMBFE74 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Milnacipran. Depression [6A70-6A7Z] [77]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Tramadol and Escitalopram. Depression [6A70-6A7Z] [95]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Tramadol and Tranylcypromine. Depression [6A70-6A7Z] [85]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Tramadol and Desvenlafaxine. Depression [6A70-6A7Z] [85]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Tramadol and OPC-34712. Depression [6A70-6A7Z] [76]
Phenelzine DMHIDUE Major Increased risk of lowers seizure threshold by the combination of Tramadol and Phenelzine. Depression [6A70-6A7Z] [85]
Clomipramine DMINRKW Major Increased risk of lowers seizure threshold by the combination of Tramadol and Clomipramine. Depression [6A70-6A7Z] [70]
Trazodone DMK1GBJ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Trazodone. Depression [6A70-6A7Z] [85]
Amitriptyline DMK7F9S Major Increased risk of lowers seizure threshold by the combination of Tramadol and Amitriptyline. Depression [6A70-6A7Z] [70]
Amoxapine DMKITQE Major Increased risk of lowers seizure threshold by the combination of Tramadol and Amoxapine. Depression [6A70-6A7Z] [70]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Tramadol and Mirtazapine. Depression [6A70-6A7Z] [85]
Protriptyline DMNHTZI Major Increased risk of lowers seizure threshold by the combination of Tramadol and Protriptyline. Depression [6A70-6A7Z] [70]
Doxepin DMPI98T Major Increased risk of lowers seizure threshold by the combination of Tramadol and Doxepin. Depression [6A70-6A7Z] [70]
Maprotiline DMPWB7T Major Increased risk of lowers seizure threshold by the combination of Tramadol and Maprotiline. Depression [6A70-6A7Z] [70]
Venlafaxine DMR6QH0 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Venlafaxine. Depression [6A70-6A7Z] [85]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Tramadol and Esketamine. Depression [6A70-6A7Z] [77]
Hyoscyamine DM804UR Moderate Additive antimotility effects by the combination of Tramadol and Hyoscyamine. Digestive system disease [DE2Z] [71]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Tramadol and Mepenzolate. Digestive system disease [DE2Z] [71]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Tramadol and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [96]
Oxybutynine DMJPBAX Moderate Additive antimotility effects by the combination of Tramadol and Oxybutynine. Discovery agent [N.A.] [71]
PMID28870136-Compound-48 DMPIM9L Major Increased risk of lowers seizure threshold by the combination of Tramadol and PMID28870136-Compound-48. Discovery agent [N.A.] [70]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Tramadol and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [69]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Tramadol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [74]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Tramadol and Deutetrabenazine. Dystonic disorder [8A02] [97]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Tramadol and Ingrezza. Dystonic disorder [8A02] [98]
Piperazine DMTY9LU Major Increased risk of lowers seizure threshold by the combination of Tramadol and Piperazine. Enterobiasis [1F65] [70]
Fenfluramine DM0762O Major Increased risk of lowers seizure threshold by the combination of Tramadol and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [85]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Tramadol and Diazepam. Epilepsy/seizure [8A61-8A6Z] [76]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Tramadol and Primidone. Epilepsy/seizure [8A61-8A6Z] [76]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Tramadol and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [89]
Stiripentol DMMSDOY Moderate Decreased metabolism of Tramadol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [99]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Tramadol and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [76]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Tramadol and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [76]
Carbamazepine DMZOLBI Moderate Increased metabolism of Tramadol caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [78]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Tramadol and Dantrolene. Fever [MG26] [76]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Tramadol and Solifenacin. Functional bladder disorder [GC50] [71]
Mirabegron DMS1GYT Moderate Decreased metabolism of Tramadol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [100]
Tolterodine DMSHPW8 Moderate Additive antimotility effects by the combination of Tramadol and Tolterodine. Functional bladder disorder [GC50] [71]
Darifenacin DMWXLYZ Moderate Additive antimotility effects by the combination of Tramadol and Darifenacin. Functional bladder disorder [GC50] [71]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Tramadol and Pentamidine. Fungal infection [1F29-1F2F] [74]
Terbinafine DMI6HUW Moderate Decreased metabolism of Tramadol caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [101]
Fluconazole DMOWZ6B Moderate Increased risk of prolong QT interval by the combination of Tramadol and Fluconazole. Fungal infection [1F29-1F2F] [74]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Tramadol caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [74]
Propantheline DM2EN6G Moderate Additive antimotility effects by the combination of Tramadol and Propantheline. Gastric ulcer [DA60] [71]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Tramadol and Cisapride. Gastro-oesophageal reflux disease [DA22] [74]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Tramadol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [74]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Tramadol and Brimonidine. Glaucoma [9C61] [102]
Cycloserine DMT1I52 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Cycloserine. HIV-infected patients with tuberculosis [1B10-1B14] [70]
Procarbazine DMIK367 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Procarbazine. Hodgkin lymphoma [2B30] [85]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Tramadol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [103]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Tramadol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Tramadol and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [105]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Tramadol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [106]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Tramadol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [74]
Ritonavir DMU764S Moderate Decreased metabolism of Tramadol caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [107]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Tramadol caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [77]
Givosiran DM5PFIJ Moderate Decreased metabolism of Tramadol caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [108]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Tramadol and Belladonna. Infectious gastroenteritis/colitis [1A40] [71]
Rimantadine DM5DWMU Major Increased risk of lowers seizure threshold by the combination of Tramadol and Rimantadine. Influenza [1E30-1E32] [70]
Amantadine DMS3YE9 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Amantadine. Influenza [1E30-1E32] [70]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Tramadol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [109]
Temazepam DM02A65 Major Additive CNS depression effects by the combination of Tramadol and Temazepam. Insomnia [7A00-7A0Z] [76]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Tramadol and Suvorexant. Insomnia [7A00-7A0Z] [76]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Tramadol and Amobarbital. Insomnia [7A00-7A0Z] [76]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Tramadol and Ramelteon. Insomnia [7A00-7A0Z] [76]
Eszopiclone DM8RZ9H Major Additive CNS depression effects by the combination of Tramadol and Eszopiclone. Insomnia [7A00-7A0Z] [76]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Tramadol and Flurazepam. Insomnia [7A00-7A0Z] [76]
Butabarbital DMC5AST Major Additive CNS depression effects by the combination of Tramadol and Butabarbital. Insomnia [7A00-7A0Z] [76]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Tramadol and Triazolam. Insomnia [7A00-7A0Z] [76]
Pentobarbital DMFNH7L Major Additive CNS depression effects by the combination of Tramadol and Pentobarbital. Insomnia [7A00-7A0Z] [76]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Tramadol and Zaleplon. Insomnia [7A00-7A0Z] [76]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Tramadol and Propiomazine. Insomnia [7A00-7A0Z] [76]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Tramadol and Tasimelteon. Insomnia [7A00-7A0Z] [76]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Tramadol and Paraldehyde. Insomnia [7A00-7A0Z] [76]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Tramadol and ITI-007. Insomnia [7A00-7A0Z] [76]
Zolpidem DMWOSKJ Major Additive CNS depression effects by the combination of Tramadol and Zolpidem. Insomnia [7A00-7A0Z] [76]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Tramadol and Quazepam. Insomnia [7A00-7A0Z] [76]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Tramadol and Estazolam. Insomnia [7A00-7A0Z] [76]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Tramadol and Polyethylene glycol. Irritable bowel syndrome [DD91] [74]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Phenolphthalein. Irritable bowel syndrome [DD91] [74]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Tramadol and Clidinium. Irritable bowel syndrome [DD91] [71]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Tramadol and Dicyclomine. Irritable bowel syndrome [DD91] [71]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Tramadol and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [76]
Amifampridine DMK08L3 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Amifampridine. Lambert-Eaton syndrome [8C62] [70]
Nelarabine DMB6VEG Major Increased risk of lowers seizure threshold by the combination of Tramadol and Nelarabine. Leukaemia [2A60-2B33] [70]
Physostigmine DM2N0TO Major Increased risk of lowers seizure threshold by the combination of Tramadol and Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [70]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Tramadol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [78]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Tramadol and Crizotinib. Lung cancer [2C25] [110]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Tramadol and Ceritinib. Lung cancer [2C25] [74]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Tramadol caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [111]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Tramadol and Osimertinib. Lung cancer [2C25] [112]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Tramadol and Selpercatinib. Lung cancer [2C25] [78]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Tramadol and Lumefantrine. Malaria [1F40-1F45] [113]
Meprobamate DMHM93Y Major Additive CNS depression effects by the combination of Tramadol and Meprobamate. Malaria [1F40-1F45] [76]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Tramadol and Halofantrine. Malaria [1F40-1F45] [114]
Chloroquine DMSI5CB Major Increased risk of lowers seizure threshold by the combination of Tramadol and Chloroquine. Malaria [1F40-1F45] [70]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Quinine. Malaria [1F40-1F45] [74]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Tramadol and Primaquine. Malaria [1F40-1F45] [74]
Mefloquine DMWT905 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Mefloquine. Malaria [1F40-1F45] [70]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [78]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Tramadol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [115]
Blinatumomab DMGECIJ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Blinatumomab. Mature B-cell lymphoma [2A85] [70]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Tramadol and Vemurafenib. Melanoma [2C30] [74]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Tramadol and LGX818. Melanoma [2C30] [116]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Tramadol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [117]
Zolmitriptan DM1IB4Q Major Additive serotonergic effects by the combination of Tramadol and Zolmitriptan. Migraine [8A80] [118]
Dihydroergotamine DM5IKUF Major Additive serotonergic effects by the combination of Tramadol and Dihydroergotamine. Migraine [8A80] [118]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Tramadol and Almogran. Migraine [8A80] [118]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Tramadol and Frovatriptan. Migraine [8A80] [118]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Tramadol and Rizatriptan. Migraine [8A80] [118]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Tramadol and Naratriptan. Migraine [8A80] [118]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Tramadol and Sumatriptan. Migraine [8A80] [118]
Eletriptan DMW649X Major Additive serotonergic effects by the combination of Tramadol and Eletriptan. Migraine [8A80] [118]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Tramadol and Lasmiditan. Migraine [8A80] [119]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Tramadol and Flibanserin. Mood disorder [6A60-6E23] [120]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Tramadol and Panobinostat. Multiple myeloma [2A83] [121]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Tramadol and Thalidomide. Multiple myeloma [2A83] [122]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Tramadol and Siponimod. Multiple sclerosis [8A40] [77]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Tramadol and Fingolimod. Multiple sclerosis [8A40] [74]
Dalfampridine DMM0PDO Major Increased risk of lowers seizure threshold by the combination of Tramadol and Dalfampridine. Multiple sclerosis [8A40] [70]
Ozanimod DMT6AM2 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Ozanimod. Multiple sclerosis [8A40] [123]
Carisoprodol DMWR1JC Major Additive CNS depression effects by the combination of Tramadol and Carisoprodol. Musculoskeletal disorder [FA00-FC0Z] [76]
Neostigmine DM6T2J3 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Neostigmine. Myasthenia gravis [8C6Y] [70]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Tramadol and Romidepsin. Mycosis fungoides [2B01] [74]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Tramadol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [78]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Tramadol and Nilotinib. Myeloproliferative neoplasm [2A20] [74]
Imatinib DM7RJXL Moderate Decreased metabolism of Tramadol caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [124]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Tramadol and Dasatinib. Myeloproliferative neoplasm [2A20] [125]
Prasugrel DM7MT6E Moderate Altered absorption of Tramadol due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [126]
Dextroamphetamine DMMIHVP Major Increased risk of lowers seizure threshold by the combination of Tramadol and Dextroamphetamine. Narcolepsy [7A20] [70]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Tramadol and Droperidol. Nausea/vomiting [MD90] [74]
Prochlorperazine DM53SRA Major Increased risk of lowers seizure threshold by the combination of Tramadol and Prochlorperazine. Nausea/vomiting [MD90] [70]
Promethazine DM6I5GR Major Increased risk of lowers seizure threshold by the combination of Tramadol and Promethazine. Nausea/vomiting [MD90] [70]
Rolapitant DM8XP26 Moderate Decreased metabolism of Tramadol caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [127]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Tramadol and Palonosetron. Nausea/vomiting [MD90] [74]
Metoclopramide DMFA5MY Major Increased risk of lowers seizure threshold by the combination of Tramadol and Metoclopramide. Nausea/vomiting [MD90] [70]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Tramadol and Granisetron. Nausea/vomiting [MD90] [74]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Tramadol and Dolasetron. Nausea/vomiting [MD90] [74]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Tramadol and Ondansetron. Nausea/vomiting [MD90] [74]
Thiethylperazine DMU3IET Major Increased risk of lowers seizure threshold by the combination of Tramadol and Thiethylperazine. Nausea/vomiting [MD90] [70]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Bupropion. Nicotine use disorder [6C4A] [70]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Tramadol and Entrectinib. Non-small cell lung cancer [2C25] [77]
Phendimetrazine DM6TS1N Major Increased risk of lowers seizure threshold by the combination of Tramadol and Phendimetrazine. Obesity [5B80-5B81] [70]
Amfepramone DM9YSNQ Major Increased risk of lowers seizure threshold by the combination of Tramadol and Amfepramone. Obesity [5B80-5B81] [70]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Tramadol and Sibutramine. Obesity [5B80-5B81] [85]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Tramadol and Lorcaserin. Obesity [5B80-5B81] [128]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Tramadol and Dexfenfluramine. Obesity [5B80-5B81] [85]
Phenylpropanolamine DMTFK3O Major Increased risk of lowers seizure threshold by the combination of Tramadol and Phenylpropanolamine. Obesity [5B80-5B81] [70]
Mazindol DMZ36RN Major Increased risk of lowers seizure threshold by the combination of Tramadol and Mazindol. Obesity [5B80-5B81] [70]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Tramadol and Levomethadyl Acetate. Opioid use disorder [6C43] [78]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Tramadol and Lofexidine. Opioid use disorder [6C43] [74]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Tramadol and Apraclonidine. Optic nerve disorder [9C40] [102]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Rucaparib. Ovarian cancer [2C73] [74]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Tramadol and Triclabendazole. Parasitic worm infestation [1F90] [74]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Tramadol and Safinamide. Parkinsonism [8A00] [85]
Rasagiline DM3WKQ4 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Rasagiline. Parkinsonism [8A00] [85]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Tramadol and Pimavanserin. Parkinsonism [8A00] [76]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Tramadol and Orphenadrine. Parkinsonism [8A00] [76]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Tramadol and Apomorphine. Parkinsonism [8A00] [74]
Abametapir DM2RX0I Moderate Decreased metabolism of Tramadol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [129]
Lindane DMB8CNL Major Increased risk of lowers seizure threshold by the combination of Tramadol and Lindane. Pediculosis [1G00] [70]
Methylscopolamine DM5VWOB Moderate Additive antimotility effects by the combination of Tramadol and Methylscopolamine. Peptic ulcer [DA61] [71]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Tramadol and Famotidine. Peptic ulcer [DA61] [77]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Tramadol and Macimorelin. Pituitary gland disorder [5A60-5A61] [130]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Tramadol and Lefamulin. Pneumonia [CA40] [131]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Tramadol and Ritodrine. Preterm labour/delivery [JB00] [83]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Tramadol and Degarelix. Prostate cancer [2C82] [78]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Tramadol and ABIRATERONE. Prostate cancer [2C82] [77]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Tramadol and Nilutamide. Prostate cancer [2C82] [78]
Enzalutamide DMGL19D Major Increased risk of lowers seizure threshold by the combination of Tramadol and Enzalutamide. Prostate cancer [2C82] [70]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Tramadol and Flutamide. Prostate cancer [2C82] [78]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Tramadol and Relugolix. Prostate cancer [2C82] [78]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Tramadol and Bicalutamide. Prostate cancer [2C82] [78]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Tramadol and Alfuzosin. Prostate hyperplasia [GA90] [74]
Levomepromazine DMIKFEL Major Increased risk of lowers seizure threshold by the combination of Tramadol and Levomepromazine. Psychotic disorder [6A20-6A25] [70]
Fluphenazine DMIT8LX Major Additive CNS depression effects by the combination of Tramadol and Fluphenazine. Psychotic disorder [6A20-6A25] [132]
Triflupromazine DMKFQJP Major Additive CNS depression effects by the combination of Tramadol and Triflupromazine. Psychotic disorder [6A20-6A25] [76]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Tramadol and Sorafenib. Renal cell carcinoma [2C90] [74]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Tramadol and Gatifloxacin. Respiratory infection [CA07-CA4Z] [86]
Doxapram DMCYANK Major Increased risk of lowers seizure threshold by the combination of Tramadol and Doxapram. Respiratory system disease [CB40-CB7Z] [70]
Celecoxib DM6LOQU Moderate Decreased metabolism of Tramadol caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [133]
Oxamniquine DM2QDX1 Major Increased risk of lowers seizure threshold by the combination of Tramadol and Oxamniquine. Schistosomiasis [1F86] [70]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Tramadol and Quetiapine. Schizophrenia [6A20] [74]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Tramadol and Mesoridazine. Schizophrenia [6A20] [74]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Tramadol and Thioridazine. Schizophrenia [6A20] [74]
Aripiprazole DM3NUMH Major Increased risk of prolong QT interval by the combination of Tramadol and Aripiprazole. Schizophrenia [6A20] [77]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Tramadol and Iloperidone. Schizophrenia [6A20] [74]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Tramadol and Paliperidone. Schizophrenia [6A20] [76]
Loxapine DM8AI9U Major Additive CNS depression effects by the combination of Tramadol and Loxapine. Schizophrenia [6A20] [132]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Tramadol and Haloperidol. Schizophrenia [6A20] [74]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Tramadol and Perphenazine. Schizophrenia [6A20] [76]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Tramadol and Molindone. Schizophrenia [6A20] [76]
Chlorpromazine DMBGZI3 Major Additive CNS depression effects by the combination of Tramadol and Chlorpromazine. Schizophrenia [6A20] [132]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Tramadol and Thiothixene. Schizophrenia [6A20] [132]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Tramadol and Clozapine. Schizophrenia [6A20] [74]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Tramadol and Trifluoperazine. Schizophrenia [6A20] [76]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Tramadol and Ziprasidone. Schizophrenia [6A20] [74]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Tramadol and Risperidone. Schizophrenia [6A20] [76]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Tramadol and Amisulpride. Schizophrenia [6A20] [134]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Tramadol and Asenapine. Schizophrenia [6A20] [74]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Tramadol and Pimozide. Schizophrenia [6A20] [78]
Fentanyl DM8WAHT Major Increased risk of lowers seizure threshold by the combination of Tramadol and Fentanyl. Sensation disturbance [MB40] [70]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Tramadol and Sufentanil. Sensation disturbance [MB40] [70]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Vardenafil. Sexual dysfunction [HA00-HA01] [74]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Tramadol and LEE011. Solid tumour/cancer [2A00-2F9Z] [74]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Tramadol and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [74]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Tramadol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [74]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Tramadol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [78]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Tramadol and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [74]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Tramadol and Pitolisant. Somnolence [MG42] [74]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Tramadol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [74]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Tramadol and Ibutilide. Supraventricular tachyarrhythmia [BC81] [74]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Tramadol and Adenosine. Supraventricular tachyarrhythmia [BC81] [74]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Tramadol and Zithromax. Syphilis [1A61-1A6Z] [74]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Tramadol and Anagrelide. Thrombocytosis [3B63] [74]
Brilinta DMBR01X Moderate Altered absorption of Tramadol due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [126]
Clopidogrel DMOL54H Moderate Altered absorption of Tramadol due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [126]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Tramadol and Lenvatinib. Thyroid cancer [2D10] [74]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Tramadol and Cabozantinib. Thyroid cancer [2D10] [78]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Tramadol and Papaverine. Tonus and reflex abnormality [MB47] [135]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Tramadol and Tizanidine. Tonus and reflex abnormality [MB47] [76]
Trospium DMX6RTG Moderate Additive antimotility effects by the combination of Tramadol and Trospium. Tonus and reflex abnormality [MB47] [71]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Tramadol and Tacrolimus. Transplant rejection [NE84] [74]
Atropine DMEN6X7 Moderate Additive antimotility effects by the combination of Tramadol and Atropine. Unspecific substance harmful effect [NE6Z] [71]
Cinoxacin DM4EWNS Major Increased risk of lowers seizure threshold by the combination of Tramadol and Cinoxacin. Urinary tract infection [GC08] [70]
Nalidixic acid DMRM0JV Major Increased risk of lowers seizure threshold by the combination of Tramadol and Nalidixic acid. Urinary tract infection [GC08] [70]
Enoxacin DMYTE6L Major Increased risk of lowers seizure threshold by the combination of Tramadol and Enoxacin. Urinary tract infection [GC08] [70]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Tramadol and Astemizole. Vasomotor/allergic rhinitis [CA08] [74]
Methdilazine DMAUHQX Major Increased risk of lowers seizure threshold by the combination of Tramadol and Methdilazine. Vasomotor/allergic rhinitis [CA08] [70]
Trimeprazine DMEMV9D Major Increased risk of lowers seizure threshold by the combination of Tramadol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [70]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Tramadol and Cetirizine. Vasomotor/allergic rhinitis [CA08] [136]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Tramadol and Disopyramide. Ventricular tachyarrhythmia [BC71] [74]
Mexiletine DMCTE9R Major Increased risk of lowers seizure threshold by the combination of Tramadol and Mexiletine. Ventricular tachyarrhythmia [BC71] [70]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Tramadol and Procainamide. Ventricular tachyarrhythmia [BC71] [74]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Tramadol and Propafenone. Ventricular tachyarrhythmia [BC71] [74]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Tramadol and Flecainide. Ventricular tachyarrhythmia [BC71] [74]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Tramadol and Amiodarone. Ventricular tachyarrhythmia [BC71] [74]
⏷ Show the Full List of 355 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aspartame E00402 134601 Flavoring agent
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sucrose stearate E00502 9898327 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA E00607 135423095 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tramadol 50 mg tablet 50 mg Oral Tablet Oral
Tramadol 50 mg tablet 50 mg Disintegrating Tablet Oral
Tramadol 200 mg capsule 200 mg 24 HR Extended Release Oral Capsule Oral
Tramadol 300 mg capsule 300 mg 24 HR Extended Release Oral Capsule Oral
Tramadol 100 mg capsule 100 mg 24 HR Extended Release Oral Capsule Oral
Tramadol 100 mg tablet 100 mg 24 HR Extended Release Oral Tablet Oral
Tramadol 200 mg tablet 200 mg 24 HR Extended Release Oral Tablet Oral
Tramadol 200 mg tablet 200 mg 24 HR Extended Release Tablet Oral
Tramadol 100 mg tablet 100 mg 24 HR Extended Release Tablet Oral
Tramadol 300 mg tablet 300 mg 24 HR Extended Release Tablet Oral
Tramadol 150 mg capsule 150 mg 24 HR Extended Release Capsule Oral
Tramadol 150 mg capsule 150 mg 24 HR Extended Release Oral Capsule Oral
Tramadol 100 mg tablet 100 mg Matrix Delivery 24 HR Extended Release Oral Tablet Oral
Tramadol 200 mg tablet 200 mg Matrix Delivery 24 HR Extended Release Oral Tablet Oral
Tramadol 300 mg tablet 300 mg 24 HR Extended Release Oral Tablet Oral
Tramadol 300 mg tablet 300 mg Matrix Delivery 24 HR Extended Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8286).
2 Local effect of tramadol on formalin evoked flinching behavior in rats. Rev Bras Anestesiol. 2008 Jul-Aug;58(4):375-9, 371-5.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 FDA Approved Drug Products: Ultram (tramadol hydrochloride) oral tablets
6 Vazzana M, Andreani T, Fangueiro J, Faggio C, Silva C, Santini A, Garcia ML, Silva AM, Souto EB: Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8. doi: 10.1016/j.biopha.2015.01.022. Epub 2015 Feb 7.
7 Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician. 2015 Jul-Aug;18(4):395-400.
8 Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
12 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
13 Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8.
14 Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
15 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
26 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
27 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
28 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
29 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
30 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
31 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
32 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
33 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
34 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
35 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
36 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
37 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
38 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
39 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
40 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
41 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
42 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
43 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
44 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
45 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
46 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
47 Drugs that may have potential CYP2B6 interactions.
48 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
49 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
50 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
51 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
52 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
53 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
54 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
55 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
56 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
57 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
58 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
59 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
60 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
61 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
62 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
63 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
64 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
65 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
66 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
67 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
68 The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
69 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
70 Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
71 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
72 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
73 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
74 Canadian Pharmacists Association.
75 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
76 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
77 Cerner Multum, Inc. "Australian Product Information.".
78 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
79 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
80 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
81 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
82 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
83 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
84 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
85 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
86 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
87 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
88 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
89 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
90 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
91 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
92 Pisani F, Spina E, Oteri G "Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice." Epilepsia 40(Suppl 10) (1999): S48-56. [PMID: 10609604]
93 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
94 Alfaro CL, Lam YWF, Simpson J, Ereshefsky L "CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline." J Clin Psychopharmacol 19 (1999): 155-63. [PMID: 10211917]
95 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
96 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
97 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
98 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
99 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
100 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
101 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
102 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
103 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
104 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
105 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
106 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
107 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
108 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
109 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
110 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
111 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
112 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
114 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
115 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
116 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
117 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
118 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
119 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
120 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
121 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
122 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
123 Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23. [PMID: 7854515]
124 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
125 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
126 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
127 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
128 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
129 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
130 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
131 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
132 Cerner Multum, Inc. "Canadian Product Information.".
133 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
134 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
135 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
136 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.